Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Spdr S&p Oil & Gas Exp & Pr call, AZN, ABBV, ARVN, ELV, and represent 24.41% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: Spdr S&p Oil & Gas Exp & Pr call (+$297M), MRK (+$195M), ISRG (+$98M), HUM (+$87M), BIIB (+$77M), UNH (+$70M), VRTX (+$69M), JNJ (+$63M), MCK (+$58M), ARGX (+$56M).
- Started 20 new stock positions in XBI, EW, OTIC, ISRG, ERAS, RCUS, MRK, NTLA, HUM, BSX. JNJ, Spdr S&p Oil & Gas Exp & Pr call, APLS, BIIB, GLPG, ANTX, MCK, ARGX, PEN, BHC.
- Reduced shares in these 10 stocks: PFE (-$123M), Arena Pharmaceuticals (-$113M), LLY (-$95M), SGEN (-$84M), ABBV (-$84M), HOLX (-$82M), SHC (-$70M), , STVN (-$57M), BPMC (-$45M).
- Sold out of its positions in AMN, ACAD, ALNY, Arena Pharmaceuticals, DH, EQRX, TRDA, GBT, HOLX, TIL.
- Avidity Partners Management was a net buyer of stock by $692M.
- Avidity Partners Management has $4.8B in assets under management (AUM), dropping by 1.86%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 92 positions in its portfolio as reported in the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Call Option | 6.2 | $297M | NEW | 3.3M | 89.88 | |
| Astrazeneca Sponsored Adr (AZN) | 5.1 | $246M | +29% | 3.7M | 66.34 | |
| Abbvie (ABBV) | 4.9 | $238M | -26% | 1.5M | 162.11 | |
| Arvinas Ord (ARVN) | 4.1 | $196M | +15% | 2.9M | 67.30 | |
| Anthem (ELV) | 4.1 | $196M | +24% | 399k | 491.22 | |
| Merck & Co (MRK) | 4.0 | $195M | NEW | 2.4M | 82.05 | |
| Avantor (AVTR) | 4.0 | $192M | +18% | 5.7M | 33.82 | |
| Baxter International (BAX) | 3.1 | $149M | +8% | 1.9M | 77.54 | |
| Zentalis Pharmaceuticals (ZNTL) | 3.1 | $147M | +17% | 3.2M | 46.14 | |
| Biohaven Pharmaceutical Holding (BHVN) | 3.0 | $146M | +7% | 1.2M | 118.57 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.0 | $142M | +94% | 546k | 260.97 | |
| UnitedHealth (UNH) | 2.8 | $132M | +110% | 260k | 509.97 | |
| United Therapeutics Corporation (UTHR) | 2.7 | $129M | +34% | 719k | 179.41 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 2.5 | $119M | +11% | 1.1M | 105.21 | |
| Mirati Therapeutics (MRTX) | 2.4 | $115M | +72% | 1.4M | 82.22 | |
| Iveric Bio (ISEE) | 2.3 | $109M | -6% | 6.5M | 16.83 | |
| Neurocrine Biosciences (NBIX) | 2.3 | $109M | -7% | 1.2M | 93.75 | |
| Iovance Biotherapeutics (IOVA) | 2.1 | $101M | +59% | 6.0M | 16.65 | |
| Intuitive Surgical Com New (ISRG) | 2.0 | $98M | NEW | 325k | 301.68 | |
| Catalent (CTLT) | 1.8 | $87M | +12% | 782k | 110.90 | |
| Humana (HUM) | 1.8 | $87M | NEW | 199k | 435.17 | |
| Syndax Pharmaceuticals (SNDX) | 1.7 | $84M | 4.8M | 17.38 | ||
| Biogen Idec (BIIB) | 1.6 | $77M | NEW | 365k | 210.60 | |
| Ultragenyx Pharmaceutical (RARE) | 1.3 | $63M | +24% | 869k | 72.62 | |
| Johnson & Johnson (JNJ) | 1.3 | $63M | NEW | 354k | 177.23 | |
| Adicet Bio (ACET) | 1.3 | $62M | +2% | 3.1M | 19.97 | |
| Kezar Life Sciences (KZR) | 1.2 | $59M | +8% | 3.5M | 16.62 | |
| McKesson Corporation (MCK) | 1.2 | $58M | NEW | 190k | 306.13 | |
| Argenx Se Sponsored Adr (ARGX) | 1.2 | $56M | NEW | 176k | 315.31 | |
| Boston Scientific Corporation (BSX) | 1.1 | $53M | NEW | 1.2M | 44.29 | |
| Natera (NTRA) | 1.1 | $53M | +38% | 1.3M | 40.68 | |
| Edwards Lifesciences (EW) | 1.1 | $52M | NEW | 440k | 117.72 | |
| Arrowhead Pharmaceuticals (ARWR) | 0.9 | $44M | +9% | 955k | 45.99 | |
| Immunocore Hldgs Ads (IMCR) | 0.8 | $41M | +10% | 1.4M | 29.90 | |
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.8 | $40M | +53% | 1.1M | 36.34 | |
| Spdr Ser Tr S&p Biotech (XBI) | 0.8 | $40M | NEW | 440k | 89.88 | |
| Bausch Health Companies (BHC) | 0.8 | $39M | NEW | 1.7M | 22.85 | |
| Avidity Biosciences Ord (RNA) | 0.8 | $38M | +12% | 2.0M | 18.47 | |
| Insmed Com Par $.01 (INSM) | 0.7 | $32M | -6% | 1.4M | 23.50 | |
| Alphatec Hldgs Com New (ATEC) | 0.7 | $32M | 2.7M | 11.50 | ||
| Ideaya Biosciences (IDYA) | 0.6 | $30M | +5% | 2.7M | 11.19 | |
| Chemocentryx (CCXI) | 0.6 | $30M | +82% | 1.2M | 25.07 | |
| Axsome Therapeutics (AXSM) | 0.6 | $29M | -8% | 711k | 41.39 | |
| Arcus Biosciences Incorporated (RCUS) | 0.6 | $29M | NEW | 912k | 31.56 | |
| Intellia Therapeutics (NTLA) | 0.6 | $28M | NEW | 390k | 72.67 | |
| Phathom Pharmaceuticals (PHAT) | 0.6 | $27M | +2% | 1.9M | 13.61 | |
| Caribou Biosciences (CRBU) | 0.5 | $26M | +5% | 2.8M | 9.18 | |
| Nuvation Bio Com Cl A (NUVB) | 0.5 | $26M | -34% | 4.9M | 5.26 | |
| Bellus Health Com New (BLU) | 0.5 | $25M | -2% | 3.7M | 6.88 | |
| Seaspine Holdings (SPNE) | 0.5 | $24M | 2.0M | 12.16 | ||
| Penumbra (PEN) | 0.5 | $23M | NEW | 104k | 222.13 | |
| Si-bone (SIBN) | 0.5 | $23M | 1.0M | 22.60 | ||
| Vir Biotechnology (VIR) | 0.4 | $20M | +11% | 780k | 25.72 | |
| Miragen Therapeutics (VRDN) | 0.4 | $19M | -18% | 1.0M | 18.49 | |
| Blueprint Medicines (BPMC) | 0.4 | $19M | -70% | 291k | 63.88 | |
| Altimmune Com New (ALT) | 0.4 | $17M | +3% | 2.9M | 6.09 | |
| Essa Pharma Com New (EPIX) | 0.3 | $15M | 2.5M | 6.18 | ||
| Seagen (SGEN) | 0.3 | $14M | -85% | 100k | 144.05 | |
| Galapagos Nv Spon Adr (GLPG) | 0.3 | $13M | NEW | 215k | 62.02 | |
| Century Therapeutics (IPSC) | 0.2 | $11M | 865k | 12.59 | ||
| Alpine Immune Sciences (ALPN) | 0.2 | $11M | -10% | 1.2M | 8.97 | |
| Apellis Pharmaceuticals (APLS) | 0.2 | $11M | NEW | 210k | 50.81 | |
| An2 Therapeutics (ANTX) | 0.2 | $10M | NEW | 688k | 15.07 | |
| Erasca (ERAS) | 0.2 | $8.6M | NEW | 995k | 8.60 | |
| Sentinelone Cl A (S) | 0.2 | $7.9M | 205k | 38.74 | ||
| Cyteir Therapeutics (CYT) | 0.1 | $7.0M | 1.9M | 3.77 | ||
| Phasebio Pharmaceuticals (PHAS) | 0.1 | $5.8M | 4.4M | 1.32 | ||
| Caremax Com Cl A (CMAX) | 0.1 | $5.6M | -8% | 755k | 7.47 | |
| Tango Therapeutics (TNGX) | 0.1 | $5.5M | +2% | 721k | 7.58 | |
| Hyperfine Com Cl A (HYPR) | 0.1 | $5.3M | 1.5M | 3.54 | ||
| Medicus Sciences Acquisition Cl A Shs (MSAC) | 0.1 | $5.1M | 520k | 9.78 | ||
| Bcls Acquisition Corp Com Cl A (BLSA) | 0.1 | $4.9M | 500k | 9.87 | ||
| Dynamics Special Purpose Cor Class A Com | 0.1 | $4.9M | 500k | 9.87 | ||
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.1 | $4.9M | 500k | 9.80 | ||
| Panacea Acquisition Corp Ii Cl A Shs (PANA) | 0.1 | $4.9M | 500k | 9.75 | ||
| Helix Acquisition Corp Com Cl A | 0.1 | $4.4M | 400k | 11.10 | ||
| Field Trip Health Ord | 0.1 | $4.0M | -7% | 3.0M | 1.34 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.1 | $4.0M | 400k | 9.91 | ||
| Graphite Bio (GRPH) | 0.1 | $3.6M | 710k | 5.10 | ||
| Oncosec Medical Incorporated (ONCS) | 0.1 | $3.4M | 2.9M | 1.15 | ||
| Otonomy (OTIC) | 0.1 | $3.2M | NEW | 1.3M | 2.40 | |
| Sema4 Holdings Corp Com Cl A (SMFR) | 0.1 | $2.9M | 950k | 3.07 | ||
| Compass Therapeutics (CMPX) | 0.1 | $2.7M | 2.0M | 1.37 | ||
| Gritstone Oncology Ord (GRTS) | 0.0 | $2.3M | -87% | 560k | 4.12 | |
| Science 37 Holdings (SNCE) | 0.0 | $2.3M | +9% | 430k | 5.35 | |
| Scynexis Com New (SCYX) | 0.0 | $2.1M | -75% | 544k | 3.91 | |
| Social Cap Suvretta Hld Crpi Class A Ord Shs | 0.0 | $2.0M | 200k | 9.90 | ||
| Social Cap Suvretta Hlds Crp Class A Ord Shs | 0.0 | $2.0M | 200k | 9.89 | ||
| Social Cap Suvretta Hlds Crp Class A Ord Shs (DNAB) | 0.0 | $2.0M | 200k | 9.75 | ||
| Social Cap Suvretta Hlds Cp Class A Ord Shs (DNAD) | 0.0 | $1.9M | 200k | 9.74 | ||
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $76k | 100k | 0.76 | ||
| Medicus Sciences Acquisition *w Exp 02/12/202 (MSACW) | 0.0 | $25k | 58k | 0.43 |
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2022 Q1 filed May 16, 2022
- Avidity Partners Management 2021 Q4 filed Feb. 14, 2022
- Avidity Partners Management 2021 Q3 filed Nov. 15, 2021
- Avidity Partners Management 2021 Q2 filed Aug. 16, 2021
- Avidity Partners Management 2021 Q1 filed May 17, 2021
- Avidity Partners Management 2020 Q4 filed Feb. 16, 2021
- Avidity Partners Management 2020 Q3 filed Nov. 16, 2020
- Avidity Partners Management 2020 Q2 filed Aug. 14, 2020
- Avidity Partners Management 2019 Q4 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 filed May 15, 2020
- Avidity Partners Management 2019 Q4 filed Feb. 14, 2020